The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Characterizing mesotheliomas with germline BAP1 mutations
Michele Carbone, MD, PhD, University of Hawaii Cancer Center, Honolulu, HI, comments on the distinction between mesothelioma variants, highlighting that a specific variant associated with a germline BAP1 mutation is distinct from the more aggressive form. It is characterized by its superficial growth and minimal invasion, and a vast majority of patients with this variant respond to therapy and can be cured. This variant is often mislabeled as mesothelioma online, leading to unrealistic patient expectations. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we have been studying these families affected by mesothelioma for 27 years and we published the results that are impressive in JTO that this variant of mesothelioma is a different disease and we need to call it differently because otherwise patients go on the web and they find that mesothelioma is a terrible disease that cannot be cured. Instead, most of the patients who develop mesothelioma because they carry a germline mutation of BAP1, they respond to therapy and they can live many years...
So we have been studying these families affected by mesothelioma for 27 years and we published the results that are impressive in JTO that this variant of mesothelioma is a different disease and we need to call it differently because otherwise patients go on the web and they find that mesothelioma is a terrible disease that cannot be cured. Instead, most of the patients who develop mesothelioma because they carry a germline mutation of BAP1, they respond to therapy and they can live many years. Many of them have died of old age. So this is a variant of mesothelioma that grows on the surface, minimally invades, but does not deeply invade into other organs or into the chest wall. The majority of these patients, 90% of these patients, respond to therapy and they can be cured.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
